Collaboration with large pharma and biotech through strategic partnering deals can represent a critical component of an early-stage biopharma ventures de-risking process. It can also validate an early-stage ventures potential for further rounds of funding.
This interactive panel brings together business development executives from large pharma and biotech, legal experts in term sheet negotiations, and early-stage founders with successful strategic partnership agreements with industry to discuss their views on the structure of the term sheet in depth.
Topics to be discussed will include:
• Upfront payments: How much? and how is this valued?
• Milestone payments: How many should be included? And how does ‘book value’ vs ‘market value’ impact the generation of these numbers?
• Royalties: What are ideal percentages and how are they defined
• Negotiation tactics: How can one reach an ideal partnership with an optimized structure for the firm poising it for further growth.